Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974321 | 0.82 | EPHX2 (0.70) | EPHX2BRAFMAPK14KDRGAA | |
| SCHEMBL11926736 | 0.81 | KDM4E (0.65) | EPHX2BRAFMAPK14KDRGAA | |
| Hydrochloric Acid SCHEMBL6336743 | 0.80 | FAAH (0.60) | SMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL27647454 | 0.78 | KMT2A (0.61) | GAASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL21659595 | 0.76 | NPC1 (0.58) | GAASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL7862109 | 0.76 | KDR (0.63) | EPHX2BRAFMAPK14KDRGAA | |
| SCHEMBL1801810 | 0.76 | CD274 (0.62) | EPHX2BRAFMAPK14KDRGAA | |
| SCHEMBL31289932 | 0.75 | EPHX2 (0.65) | EPHX2BRAFMAPK14KDRGAA | |
| Hydrochloric Acid SCHEMBL10768966 | 0.75 | EPHX2 (0.57) | EPHX2BRAFMAPK14KDRGAA | |
| SCHEMBL10378 | 0.74 | LIPE (0.58) | EPHX2KDRGAASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | EPHX2 3190/4885BLM 619/4885BRAF 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.